Staying well-hydrated and managing gastrointestinal side effects can help prevent dehydration
Prior authorization required: Some plans cover Ozempic but require prior authorization
Across the SURPASS trials documented in the Mounjaro FDA prescribing information, injection-site reactions occurred in approximately 3-7% of participants depending on dose, while true systemic allergic responses (hives spreading beyond the site, facial swelling, breathing difficulty) are rare
Healthcare providers are equipped with the knowledge and tools to monitor and address any potential side effects, ensuring that patients can comfortably adhere to their treatment plans without unnecessary disruptions
Consideration of a cyclical delivery of semaglutide, and other AOMs, could be considered, where semaglutide is administered until a pre-determined body weight is achieved, at which point an interval period is commenced until a pre-determined percentage of weight is regained, before restarting treatment
The results from these trials are promising, and Semaglutide has quickly become a popular option for weight loss treatment
